2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

Stockheads

24 Jan 2023

Link copied to clipboard

Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies.

In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.

Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.

To hear about the company’s upcoming 2023, click above.

Explore More

Investor Guide: Health & Biotech FY2023

Read MoreHealth

Link copied to clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

"*" indicates required fields

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

Featured Companies

ASX: PTX Prescient Therapeutics

You might be interested in

Year in Review

Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke

December 1, 2022 | Stockhead TV

Prepped and Primed

2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner

January 23, 2023 | Stockhead TV

Health & Biotech

ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow

January 20, 2023 | Nadine McGrath

Sponsored Articles

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2305968169"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2305968169\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2305968169?lang=en_US&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-Prescient-1-640x360.jpg","is_english":true,"pubTime":"2023-01-24 07:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2305968169","market":"us","top_or_hot":-1,"title":"2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke","media":"Stockheads","content":"<html><body><div>\n<main role=\"main\">\n<div><div></div></div>\n<div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div><p><strong>Stockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. </strong></p>\n<p>In this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.</p>\n<p>Prescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.</p>\n<p><strong>To hear about the company’s upcoming 2023, click above.</strong></p>\n<span></span><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-1024x578.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-768x433.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-610x344.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1-640x361.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/09/SH_Health-and-Biotech-Investor-guide-1080x720-1.jpg 1196w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2023</span> </li> </ul></div><div></div><div><span>Read More</span>Health</div><div></div><div><div><div><img height=\"40\" src=\"https://stockhead.com.au/wp-content/themes/stockhead_lee_mic_v2/images/social-share/check-icon.png\" width=\"40\"/></div><div><p>Link copied to clipboard</p></div></div>\n<div>\n<div></div>\n<div>\n<div>\n<button></button>\n<div>\n<div>\n<h2>SUBSCRIBE</h2><p>Get the latest Stockhead news delivered free to your inbox.</p> </div>\n<div>\n<div>\n<div>\n<p>\"<span>*</span>\" indicates required fields</p>\n</div><form action=\"/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/\" enctype=\"multipart/form-data\" method=\"post\" novalidate=\"\" target=\"gform_ajax_frame_2\">\n<div><div><div><label for=\"input_2_1\">Name<span><span>*</span></span></label><div><input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Name\" type=\"text\" value=\"\"/> </div></div><div><label for=\"input_2_2\">Email<span><span>*</span></span></label><div>\n<input aria-invalid=\"false\" aria-required=\"true\" placeholder=\"Email\" type=\"email\" value=\"\"/>\n</div></div><fieldset><div><i></i><span>Hidden</span></div><legend>Email Lists</legend><div><div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Morning Update\"/>\n<label for=\"choice_2_5_1\">Morning Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Lunch Update\"/>\n<label for=\"choice_2_5_2\">Lunch Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Market Close Update\"/>\n<label for=\"choice_2_5_3\">Market Close Update</label>\n</div><div>\n<input checked=\"checked\" type=\"checkbox\" value=\"Weekend Update\"/>\n<label for=\"choice_2_5_4\">Weekend Update</label>\n</div></div></div></fieldset><div><label for=\"input_2_3\"></label><div></div></div></div></div>\n<div> <input type=\"submit\" value=\"Submit\"/> <input type=\"hidden\" value=\"form_id=2&amp;title=&amp;description=&amp;tabindex=0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"2\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"WyJbXSIsImQ5ODZkNzIwYjIxZjU4YzcxYzQzNTI1YjUzYTViYTYxIl0=\"/>\n<input type=\"hidden\" value=\"0\"/>\n<input type=\"hidden\" value=\"1\"/>\n<input type=\"hidden\" value=\"\"/>\n</div>\n</form>\n</div>\n<p>\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t</p>\n</div>\n</div>\n<div>\n<p>\n\t\t\t\t\t\t\tBy proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.\n\t\t\t\t\t\t</p>\n</div>\n</div>\n</div>\n</div>\n</div><div> <h3>Featured Companies</h3> <ul><li> <span>ASX: PTX</span> <span>Prescient Therapeutics </span> </li></ul></div><div> <div> <h2>You might be interested in</h2> </div> <div><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2022/11/YIR-Prescient-Therapeutics.jpg 1200w\" width=\"300\"/> </div> <header> <p>Year in Review</p> <h2>Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke</h2> <p> <span> <time datetime=\"2022-12-01 10:24:20\">December 1, 2022</time> <time datetime=\"2022-12-01 12:47:22\" december=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-PharmAust.jpg 1200w\" width=\"300\"/> </div> <header> <p>Prepped and Primed</p> <h2>2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner</h2> <p> <span> <time datetime=\"2023-01-23 09:30:23\">January 23, 2023</time> <time datetime=\"2023-01-23 13:46:10\" january=\"\"> </time></span> |      <span> <span> Stockhead TV </span> </span> </p> </header></article><article> <div> <img decoding=\"async\" height=\"169\" loading=\"lazy\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2023/01/Garden-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-610x343.jpg 610w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2023/01/Garden.jpg 1200w\" width=\"300\"/> </div> <header> <p>Health &amp; Biotech</p> <h2>ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow</h2> <p> <span> <time datetime=\"2023-01-20 14:22:59\">January 20, 2023</time> <time datetime=\"2023-01-20 14:22:59\" january=\"\"> </time></span> |      <span> <span> Nadine McGrath </span> </span> </p> </header></article> </div></div>\n<div></div>\n<div></div>\n<div><h2>Sponsored Articles</h2></div>\n</main>\n</div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2023 Prepped and Primed: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-24 07:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://stockhead.com.au/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/><strong>Stockheads</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Link copied to clipboardStockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX ...</p>\n\n<a href=\"https://stockhead.com.au/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/2023-prepped-and-primed-prescient-therapeutics-asxptx-with-ceo-and-managing-director-steven-yatomi-clarke/","article_id":"2305968169","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2023/01/PAP-2023-Prescient-1-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2305968169","pubTimestamp":1674515674,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Link copied to clipboardStockhead’s Prepped and Primed video series is a yearly wrap up address from","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"2023年准备和启动：先见之明治疗（ASX：PTX）与首席执行官和董事总经理史蒂文Yatomi-Clarke","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTX":1},"content_text":"Link copied to clipboardStockhead’s Prepped and Primed video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. \nIn this instalment Steven Yatomi-Clarke, CEO and managing director at Prescient Therapeutics (ASX:PTX) shares his outlook for 2023.\nPrescient Therapeutics develop a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. The company has licensed technologies from and in collaboration with world-leading cancer centres in the US and Australia.\nTo hear about the company’s upcoming 2023, click above.\n Explore More   Investor Guide: Health & Biotech FY2023  Read MoreHealthLink copied to clipboard\n\n\n\n\n\n\n\nSUBSCRIBEGet the latest Stockhead news delivered free to your inbox. \n\n\n\n\"*\" indicates required fields\n\nName* Email*\n\nHiddenEmail Lists\n\nMorning Update\n\n\nLunch Update\n\n\nMarket Close Update\n\n\nWeekend Update\n\n  \n\n\n\n\n\n\n\n\n\n\n\n\t\t\t\t\t\t\t\t\t\tIt's free. Unsubscribe whenever you want.\n\t\t\t\t\t\t\t\t\t\n\n\n\n\n\t\t\t\t\t\t\tBy proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.\n\t\t\t\t\t\t\n\n\n\n\n Featured Companies  ASX: PTX Prescient Therapeutics    You might be interested in       Year in Review Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke   December 1, 2022   |        Stockhead TV         Prepped and Primed 2023 Prepped and Primed: PharmAust (ASX:PAA) with general manager, Fiona Milner   January 23, 2023   |        Stockhead TV         Health & Biotech ScoPo’s Powerplays: ASX health stocks sprout 4.6%, as Volpara soars on first positive cash flow   January 20, 2023   |        Nadine McGrath     \n\n\nSponsored Articles","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}